February 19, 2021
Antibody Hinders EGFR Lung Cancers
Antibody hinders EGFR lung cancer: Johnson&Johnson’s drug shows succes in hindering tumor growth in 74% of lung cancer patients with EGFR mutations.
FIERCEBiotech
Research News
Explore our curated selection of the latest breakthroughs in lung cancer research.
February 19, 2021
Antibody hinders EGFR lung cancer: Johnson&Johnson’s drug shows succes in hindering tumor growth in 74% of lung cancer patients with EGFR mutations.
FIERCEBiotech
Learn more about:
LCFA prioritizes providing reliable information about new diagnostics, treatments, and prevention strategies, including exciting FDA-approved personalized therapies based on individual tumor biomarkers. Human-reviewed, AI-created content is used to create some of the summaries for the articles listed.